Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 2 clients • 8 examiners • 4 art units • 0 of 9 (0%) have an AI response strategy ready
This profile records 9 pending office actions in Biotechnology & Pharmaceuticals and 20556 career applications. The pending workload identifies current activity associated with the profile, while the application figure reflects the broader recorded prosecution base.
The resolved allowance rate is 75.45%, with an average of 3.18 office actions per allowance. This indicates a resolved allowance result below four-fifths and more than three office actions for allowed matters.
Practitioners can use the open-action figure to assess present workload and the other figures to frame historical review. The data does not show whether the reported allowance and action measures apply specifically to the Codexis matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (33%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 3 (33%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 2 | 70.7% | +42.8% |
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18660851 | RNA POLYMERASE VARIANTS | BOWERS, ERIN M | — |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | — |
| 18395294 | ENGINEERED RNA LIGASE VARIANTS | GRAY, JESSICA | — |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18971755 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | EPSTEIN, TODD MATTHEW | — |
| 18886292 | BIOCATALYSTS FOR EZETIMIBE SYNTHESIS | MEAH, MOHAMMAD Y | — |
| 18781007 | LOV-D ACYLTRANSFERASE MEDIATED ACYLATION | MEAH, MOHAMMAD Y | — |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | — |
| 18638060 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | ROBINSON, HOPE A | — |
| 18516310 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | JONES-FOSTER, ERICA NICOLE | — |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Codexis | 7 |
| Codexis Inc. | 2 |
| Art Unit | Apps |
|---|---|
| 1652 | 5 |
| 1656 | 2 |
| 1653 | 1 |
| 1682 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18971755 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | Codexis, Inc. | EPSTEIN, TODD MATTHEW | 1652 | Other | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18886292 | BIOCATALYSTS FOR EZETIMIBE SYNTHESIS | Codexis Inc. | MEAH, MOHAMMAD Y | 1652 | §112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18781007 | LOV-D ACYLTRANSFERASE MEDIATED ACYLATION | Codexis Inc. | MEAH, MOHAMMAD Y | 1652 | DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18660851 | RNA POLYMERASE VARIANTS | Codexis, Inc. | BOWERS, ERIN M | 1653 | §101§102 | Non-Final OA | — | Pending | May 10, 2024 |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | Codexis, Inc. | HUTSON, RICHARD G | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18638060 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | Codexis, Inc. | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18395294 | ENGINEERED RNA LIGASE VARIANTS | Codexis, Inc. | GRAY, JESSICA | 1682 | §102§103DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18516310 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | Codexis, Inc. | JONES-FOSTER, ERICA NICOLE | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | Codexis, Inc. | NOAKES, SUZANNE MARIE | 1656 | §101§102DP | Final Rejection | — | Pending | Oct 12, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial75.5% of resolved applications prosecuted by Fisherbroyles, LLP - Codexis, Inc. were allowed, across 20,556 applications in USPTO records.
3.18 office actions per allowed application on average.
9 pending office actions as of October 2026, for 2 clients, before 8 examiners in 4 art units.
